Researchers reveal new insights on the growth of craniopharyngioma and identified a potential therapeutic treatment.

Millions of people take metformin, a Type 2 diabetes medication that lowers blood sugar. The "wonder drug" has also been shown to slow cancer growth, improve COVID outcomes and reduce inflammation.

Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound and other anti-obesity drugs was third-highest in the ...

Pointing to an almost one per cent growth in three-month revenues which totalled $367 million, CEO Audley Reid said though ...

GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achiev ...

Based on these initial results and the upcoming 52-week readout in the second half 2025, Biomea plans to engage with the FDA to discuss the data. This meeting will provide an opportunity to align with ...

A research team from the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has identified a mechanistic link between high blood glucose levels and weakened immunity against viral ...

These drugs have been in wide medical use for quite some time—Victoza was first approved for the treatment of type 2 diabetes in 2010, for example—but they have become ... demands that Novo Nordisk ...

While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, the U.S. FDA has now approved Crenessity (crinecerfont) ...

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent ...

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was ...